← FDA DRUG APPROVALS

FDA ANDA · ANDA208237

MEMANTINE AND DONEPEZIL HYDROCHLORIDES

Sponsor: ANI PHARMS

APPLICATION
ANDA208237
TYPE
ANDA
ORIGINAL APPROVAL
2023-12-15
LATEST ACTION
2023-12-15
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDEPrescription
DONEPEZIL HYDROCHLORIDE 10MG, MEMANTINE HYDROCHLORIDE 21MG · CAPSULE, EXTENDED RELEASE · ORAL

Approval history

2023-12-15UNKNOWN · Original · standardLetterAP
2023-12-15UNKNOWN · Original · standardTA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →